There is a smorgasbord of options in the management of dyslipidaemia in visceral obesity

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.21, Iss.8, 2005-08, pp. : 10-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of diabetic dyslipidaemia

Inpharma, Vol. 1, Iss. 1482, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Canadian guidelines for the management of dyslipidaemia

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 265, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia

By Toth Peter P Davidson Michael H

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 1, 2005-01 ,pp. : 131-139

Informa Healthcare

Access to resources Recommend Favorite

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes

By Nelson Robert H Miles John M

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2483-2491

Informa Healthcare

Access to resources Recommend Favorite

Dyslipidemia in Visceral Obesity: Mechanisms, Implications, and Therapy

By Dick C. Chan Hugh P.R. Barrett Gerald F. Watts

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 4, 2004-01 ,pp. : 227-246

Adis International

Access to resources Recommend Favorite